BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32239624)

  • 21. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
    Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38451729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
    Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
    Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
    Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
    Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.
    Li L; Wang Y; Jiao L; Lin C; Lu C; Zhang K; Hu C; Ye J; Zhang D; Wu H; Feng M; He Y
    Cancer Lett; 2019 Jun; 452():191-202. PubMed ID: 30910592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
    Chen W; Yu D; Sun SY; Li F
    Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
    Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
    Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
    Sun Y; Meyers BA; Czako B; Leonard P; Mseeh F; Harris AL; Wu Q; Johnson S; Parker CA; Cross JB; Di Francesco ME; Bivona BJ; Bristow CA; Burke JP; Carrillo CC; Carroll CL; Chang Q; Feng N; Gao G; Gera S; Giuliani V; Huang JK; Jiang Y; Kang Z; Kovacs JJ; Liu CY; Lopez AM; Ma X; Mandal PK; McAfoos T; Miller MA; Mullinax RA; Peoples M; Ramamoorthy V; Seth S; Spencer ND; Suzuki E; Williams CC; Yu SS; Zuniga AM; Draetta GF; Marszalek JR; Heffernan TP; Kohl NE; Jones P
    Cancer Res; 2020 Nov; 80(21):4840-4853. PubMed ID: 32928921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
    Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD
    Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer.
    Cao L; Qin Z; Yu T; Bai X; Jiang S; Wang D; Ning F; Huang M; Jin J
    Biochem Pharmacol; 2024 Jun; 224():116207. PubMed ID: 38621425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
    Niu M; Xu J; Liu Y; Li Y; He T; Ding L; He Y; Yi Y; Li F; Guo R; Gao Y; Li R; Li L; Fu M; Hu Q; Luo Y; Zhang C; Qin K; Yi J; Yu S; Yang J; Chen H; Wang L; Li Z; Dong B; Qi S; Ouyang L; Zhang Y; Cao Y; Xiao ZJ
    Nat Commun; 2021 Oct; 12(1):5919. PubMed ID: 34635651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.
    Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S
    Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.